Form 10-Q Y-mAbs Therapeutics, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Y-mAbs Therapeutics (YMAB) PT Lowered to $25 at BMO Capital
August 12, 2024 4:08 PM EDTBMO Capital analyst Etzer Darout lowered the price target on Y-mAbs Therapeutics (NASDAQ: YMAB) to $25.00 (from $26.00) while maintaining a Outperform rating.
The analyst comments "YMAB reported 2Q24 total revenues of $22.8M, a touch below FactSet consensus (-0.9%) but ahead of our estimate (+3.6%).... More



